ABBOTT LABORATORIES vs Bristol-Myers Squibb Company, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where ABT and BMY diverge most: on revenue growth, ABT reads +6.6% and BMY reads +1.8%; on debt / equity, ABT reads 0.65 and BMY reads 2.31. The rest of the comparable metrics sit closer together. What ABT's price implies is a bet that sits within the historical range (whole-company basis). What BMY's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | ABT | BMY |
|---|---|---|
| Price | $103.11 | $62.09 |
| Market cap | $180.1B | $127.1B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +13.2% | — |
| P/E | 28.9 | 17.4 |
| P/B | 3.42 | 6.32 |
| P/S | 3.99 | 2.62 |
| EV/EBITDA | 22.6 | 45.6 |
| Revenue growth | +6.6% | +1.8% |
| Operating margin | 12.1% | — |
| Net margin | 13.9% | 15.0% |
| Return on equity | 11.9% | 36.2% |
| Return on assets | 5.7% | 8.4% |
| Return on invested capital | 6.6% | — |
| FCF yield | 4.1% | 9.4% |
| Dividend yield | 2.3% | 4.0% |
| Debt / equity | 0.65 | 2.31 |
| Current ratio | 1.39 | 1.42 |
| Altman Z (solvency) | 7.16 | 2.12 |
| Piotroski F (quality) | 6 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.